Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

NBE 002

Next Previous
X
Search
Drug Profile

NBE 002

Alternative Names: BI-3702025; NBE-002; PNU-159682-anti-ROR1 antibody drug conjugate

Latest Information Update: 28 Mar 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator NBE-Therapeutics
  • Class Anthracyclines; Antineoplastics; Cytostatic antibiotics; Drug conjugates; Immunoconjugates; Immunotherapies; Immunotoxins; Monoclonal antibodies
  • Mechanism of Action DNA intercalators; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Solid tumours; Triple negative breast cancer
  • No development reported Lung cancer; Ovarian cancer
  • Discontinued Multiple myeloma

Most Recent Events

  • 28 Mar 2024 No recent reports of development identified for phase-I development in Lung-cancer in Switzerland (IV)
  • 28 Mar 2024 No recent reports of development identified for phase-I development in Ovarian-cancer in Switzerland (IV)
  • 04 Sep 2023 NBE-Therapeutics terminates phase-I/II clinical trial in Solid tumours (Late-stage disease, Second-line therapy or greater) in USA (IV) as they ends the programme (NCT04441099)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top